Holds Public Expose, Phapros 2022 Strategy Focuses On Development Of Innovation And Digitization Strategies

Illustration. (Photo: Doc. Antara)

JAKARTA - A subsidiary of the national pharmaceutical state-owned company, PT Phapros (PEHA) held the Annual General Meeting of Shareholders for the 2021 Fiscal Year and continued with the Company's public exposure by inviting shareholders, potential investors, and the media to convey the company's achievements during 2021 and the quarter first 2022.

The annual event also contains explanations from the Board of Directors regarding the company's future strategies by responding to national and global macroeconomic conditions that have a direct or indirect impact on corporate performance.

According to the President Director of PT Phapros Tbk, Hadi Kardoko, during the past 2021, the company managed to record a fairly good financial and non-financial performance. The company managed to increase net sales by 7.23 percent in 2021 compared to 2020.

"Although the company's assets have decreased by 4 percent compared to 2020, the company has also succeeded in increasing the cash ratio in 2021 by 122 percent compared to the previous year. This indicates that the company is growing healthily and has a fairly good ability to pay its obligations", he said in Jakarta, Wednesday. May 25.

PEHA also has non-financial performance that is recognized by other parties as a form of hard work by all parties in the company, namely in the form of 9 awards and 6 certifications, including the allocation of social responsibility which increased 40 percent compared to 2020.

"Last year we also launched more than 10 new products in the therapy categories for cardiovascular, orthopedic, health supplements, gastrointestinal, neurotropic, and oral corticosteroids. With the increasing demand for quality medicinal products by the public and medical personnel, Phapros has also contributed by releasing the latest products based on research and research", he explained.

According to Hadi, this year Indonesia's macroeconomic conditions as well as the pharmaceutical sector are better than the previous year when they were still facing the pandemic. The growth of the pharmaceutical market in 2022 is predicted to reach 10.2 percent, higher than in 2021, which is only 9.4 percent. And in 2023, it is estimated that this sector will grow to reach 11.2 percent.

"This year the company will focus on growth and innovation strategies, especially on structuring the company's portfolio, optimizing subsidiaries, and structuring marketing operations. In addition, we will also carry out production efficiency, structuring research and product development, business development, and strengthening company finances", he said.

Digital transformation is also part of the company's grand strategy in 2022, including operational transformation by digitizing supply chains and production processes, as well as optimizing sales through e-commerce.

This year the company also made a change in management. Based on the results of today's GMS, it has been decided that there will be a replacement in the position of the Independent Commissioner, so that the structure of the Company's Board of Commissioners becomes:

President Commissioner: Maxi Rein Rondonuwu

Commissioner: Masrizal Achmad Syarief

Independent Commissioner: Chrisma Aryani Albandjar

Independent Commissioner: Bimo Wijayanto

As for the composition of the board of directors, there is a change in the positions of the Marketing Director and the Production Director of the Company, so that the Company's Board of Directors structure becomes:

President Director: Hadi Kardoko

Director of Finance, Risk Management, and HR: David Sidjabat

Marketing Director: Imelda Alini Pohan

Production Director: Ida Rahmi Kurniasih